Skip to main content
. 2021 Jun 29;5:62. doi: 10.1038/s41698-021-00197-w

Fig. 1. Bevacizumab reduced the CD31+Ang2+ vessel density.

Fig. 1

a Representative immunofluorescence for CD31 and Ang2 pre- and post-bevacizumab (images from paired samples of same patient); scale bar = 50 µm. Quantitative analyses of TNBC vessels (bd).